How much does Teclistamab-cqyv cost? Market reference

Teritusumab (Teclistamab-cqyv) is an innovative bispecific antibody drug developed by Janssen Biotech. It can simultaneously recognize BCMA (B cell maturation antigen) on the surface of tumor cells and CD3 on the surface of immune system T cells, thereby activating the patient's own immune cells and achieving precise elimination of leukemia and multiple myeloma cells. This mechanism is different from traditional chemotherapy and monoclonal antibody therapy. It has strong immune targeting and a long sustained response period. It is considered a major breakthrough in the treatment of multiple myeloma.

The core advantage of Teritusumab lies in the "autoimmune activation" mechanism, which does not require exogenous cell transplantation but directly awakens the killing potential of T cells in the body. Clinical application shows that the drug can significantly improve the quality of life of patients with relapsed or refractory myeloma and provide new survival opportunities for those who are ineffective with traditional treatments. In addition, it has a rapid onset of action, and disease control effects can generally be observed within a few weeks. It is one of the first BCMA-targeted dual antibodies approved for marketing in the world.

At present, the generic drug teritusumab has been officially launched in China, but it has not yet been included in the national medical insurance catalog, so the market price is relatively high. According to public channel data, the domestic version sells for approximately 30,000 to 40,000 yuan per box. The specific price will vary slightly depending on the purchasing channel and hospital level. At the same time, the European version of the original drug is also sold in many overseas markets. Each box of 30mg/3ml is priced at about RMB 10,000, while the price of each box of 153mg/1.7ml (concentration is 90mg/ml) may be as high as RMB 50,000. It is worth noting that there are currently no generic drugs of Teritusumab on the market in the world. Therefore, whether it is the domestic version or the European version, the main way for patients to obtain the drug is through regular hospital prescriptions or overseas pharmacy channels.

Reference materials:https://www.tecvayli.com/